DNA antibody constructs encoding anti-ZIKV envelope antibodies

Patent metadata

Field	Value
Publication number	US-11925685-B2
Application number	US-201716334441-A
Country	US
Kind code	B2
Filing date	Sep 19, 2017
Priority date	Sep 19, 2016
Publication date	Mar 12, 2024
Grant date	Mar 12, 2024

Abstract

Disclosed herein is a composition comprising a recombinant nucleic acid sequence that encodes an antibody to a Zika viral antigen, and functional fragments thereof. The invention also relates to a composition comprising the combination of a first composition that elicits an immune response in a mammal against zika virus and a second composition comprising a recombinant nucleic acid sequence encoding an antibody, a fragment thereof, a variant thereof, or a combination thereof. In some instances, the nucleic acid molecule comprises a nucleotide sequence encoding an anti-ZIKV-Envelope (anti-ZIKV E) Protein antibody.

First claim

What is claimed is:

1. A nucleic acid molecule encoding one or more synthetic antibodies, wherein the nucleic acid molecule comprises at least one selected from the group consisting of
a) a nucleotide sequence encoding a variable light (VL) chain of an anti-ZIKV envelope (E) protein synthetic antibody, wherein the encoded sequence is selected from the group consisting of SEQ ID NO:2, and an antigen binding fragment thereof that retains all three LCDR regions thereof;
b) a nucleotide sequence encoding a variable heavy (VH) chain of an anti-ZIKV E protein synthetic antibody, wherein the encoded sequence is selected from the group consisting of SEQ ID NO:1, and an antigen binding fragment thereof that retains all three HCDR regions; and
c) a nucleotide sequence encoding a combination of a VL chain and VH chain of an anti-ZIKV envelope (E) protein synthetic antibody, wherein the encoded sequence is selected from the group consisting of SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:20, and an antigen binding fragment thereof that retains at least all three HCDR regions and all three LCDR regions.

2. The nucleic acid molecule of claim 1 , further comprising a nucleotide sequence encoding a cleavage domain.

3. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule comprises a nucleotide sequence encoding an anti-ZIKV E antibody.

4. The nucleic acid molecule of claim 1 , wherein the anti-ZIKV E antibody comprises an amino acid sequence selected from the group consisting of SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:20, or a fragment thereof comprising at least 85% of the full length sequence.

5. The nucleic acid molecule of claim 1 , wherein the anti-ZIKV E protein synthetic antibody comprises a variable heavy (VH) chain and a variable light (VL) chain.

6. The nucleic acid molecule of claim 5 , wherein anti-ZIKV E protein synthetic antibody VH chain comprises a sequence selected from the group consisting of SEQ ID NO:1, and a fragment thereof comprising at least 85% of the full length sequence.

7. The nucleic acid molecule of claim 5 , wherein anti-ZIKV E protein synthetic antibody VL chain comprises a sequence selected from the group consisting of SEQ ID NO:2, and a fragment thereof comprising at least 85% of the full length sequence.

8. The nucleic acid molecule of claim 1 , wherein the nucleotide sequence encodes a leader sequence.

9. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule comprises an expression vector.

10. A composition comprising the nucleic acid molecule of claim 1 .

11. The composition of claim 10 , further comprising a pharmaceutically acceptable excipient.

12. A method of inducing an immune response comprising administering the composition of claim 10 to an individual in need thereof in an amount effective to induce passive immunity in said individual.

13. The method of claim 12 , wherein the immune response is persistent.

14. The method of claim 12 , wherein the immune response is systemic.

Assignees

• Weiner David
• Muthumani Karuppiah
• Yan Jian
• Univ Pennsylvania
• Inovio Pharmaceuticals Inc
• Wistar Inst

Inventors

• Weiner David
• Muthumani Karuppiah
• Yan Jian

Classifications

• C07K16/116 Primary

  Togaviridae (F); Matonaviridae (F); Flaviviridae (F) · CPC title

• C12N2770/24133

  Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory · CPC title

• C12N2770/24122

  New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title

• C12N2770/24134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C07K2317/56

  variable (Fv) region, i.e. VH and/or VL · CPC title